-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18

Benzinga·09/09/2026 13:10:20
Listen to the news
Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.